EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

Kate Cwynarski iD, Gloria Iacoboni, Eleni Tholouli, Tobias Menne, David A Irvine, Nivetha Balasubramaniam, Leigh Wood, Justin Shang, Eric Xue, Yiyun Zhang, Silvia Basilico, Margarida Neves und 15 weitere

Nature Medicine · 2025

DOI: 10.1038/s41591-024-03326-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Nature Medicine, 2025. Verfasst von Kate Cwynarski und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University College London, London, UK. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Receptors, Antigen, T-Cell, alpha-beta. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens that discriminate malignant from normal T cells, thus avoiding severe immunosuppression consequent to depletion of the entire T cell compartment. We recently described a targeting strategy based on the mutually exclusive expression of T cell antigen receptor beta-chain constant domain (TRBC) 1 and 2. Selective targeting of the T cell antigen receptor beta-chain expressed by the (clonal) malignancy spares normal T cells expressing the other chain. The LibraT1 study is an ongoing, multicenter, international, single-arm phase 1/2 study of TRBC1-directed autologous chimeric antigen receptor (CAR) T cells (AUTO4) in relapsed/refractory TRBC1-positive PTCL. Primary objectives were assessment of safety and tolerability of AUTO4 infusion. Key secondary endpoints included efficacy, CAR T cell expansion and persistence. Here we describe the findings from dose escalation in LibraT1 in the first ten patients, in a non-prespecified interim analysis. AUTO4 resulted in low frequency of severe immunotoxicity, with one of ten patients developing grade 3 cytokine release syndrome. Complete metabolic response was observed in four of ten evaluable patients, with remissions being durable beyond 1 year in two patients. While an absence of circulating CAR T cells was observed, CAR T cells were readily detected in lymph node biopsy samples from sites of original disease suggesting homing to tumor sites. These results support the continuing exploration of TRBC1 targeting in PTCL. ClinicalTrials.gov registration: NCT03590574 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralImmunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, Antigen, T-Cell, alpha-betaT-LymphocytesHumansMaleFemaleMiddle AgedAdultAged

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell, alpha-beta

Autor:innen und Institutionen

  • Department of Haematology, University College London, London, UK.
  • University College London Hospital, London, UK.
  • Department of Haematology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Queen Elizabeth University Hospital, Glasgow, UK.

ORCID-Profile: Kate Cwynarski, Mathieu Ferrari, Paul Maciocia, Martin Pule

Zitieren

APA

Cwynarski, K., Iacoboni, G., Tholouli, E., Menne, T., Irvine, D. A., Balasubramaniam, N., Wood, L., Shang, J., Xue, E., Zhang, Y., Basilico, S., Neves, M., Raymond, M., Scott, I., El-Kholy, M., Jha, R., Dainton-Smith, H., Hussain, R., Day, W., …, & Pule, M. (2025). TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03326-7

Vancouver

Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine DA, Balasubramaniam N, et al. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial. Nature Medicine. 2025. doi:10.1038/s41591-024-03326-7

BibTeX
@article{Cwynarski2025,
  author = {Cwynarski, Kate and Iacoboni, Gloria and Tholouli, Eleni and Menne, Tobias and Irvine, David A and Balasubramaniam, Nivetha and Wood, Leigh and Shang, Justin and Xue, Eric and Zhang, Yiyun and Basilico, Silvia and Neves, Margarida and Raymond, Meera and Scott, Ian and El-Kholy, Mohamed and Jha, Ram and Dainton-Smith, Heather and Hussain, Rehan and Day, William and Ferrari, Mathieu and Thomas, Simon and Lilova, Koki and Brugger, Wolfram and Marafioti, Teresa and Lao-Sirieix, Pierre and Maciocia, Paul and Pule, Martin},
  title = {TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial},
  journal = {Nature Medicine},
  year = {2025},
  doi = {10.1038/s41591-024-03326-7}
}
Kostenlos starten →